Home Press Press Releaeses Press Releases +++ adivo’s lead oncology program granted limited marketing authorization by EMA ++++++ Helmholtz Munich: New high-tech approach to detect diseased cells at an early stage ++++++ 4GENE closes high six-figure financing round ++++++ AMSilk relocates from IZB to larger premises with plans to scale-up its production of sustainable material solutions ++++++ Immunic Secures USD 60 Million PIPE Financing ++++++ Insempra Appoints Two New Members to its Scientific Advisory Board +++ PDF archive 2018 11. October 2018Gilead Sciences, ChromoTek and Johnson & Johnson Innovation present at the Biotech Press Lounge 20. August 2018Pet therapeutic antibody firm adivo announces closure of seed-financing round 2. August 2018GNA Biosolutions, a Munich based Biotech Company, wins AACC’s Disruptive Technology Award in Chicago 14. June 2018Innovative start-ups present to leading life science investors at the IZB 26. May 2018New ways to invest in cancer drugs 22. March 2018Origenis Appoints Dr. Peter Seufer-Wasserthal as Chief Business Officer 15. March 2018Origenis Appoints Thomas Loeser as Chief Financial Officer 8. February 2018New Technologies from the IZB are revolutionizing medical diagnostics 2017 5. September 2017Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million 6. July 2017Start-ups profit from being in close contact with the venture capital scene 3. April 2017Europe-wide event series is very popular 12. January 2017Breakthrough technology improves genetic stem cell therapies 2016 10. November 2016Evotec and Oxford create novel partnership called “LAB282” 4. October 2016Evotec and Carrick Therapeutics build strategic alliance 29. September 2016Evotec receives further important pre-clinical milestone in endometriosis alliance with Bayer 13. September 2016LEUKOCARE grants license to US vaccine company PaxVax 9. June 2016Bicoll moves into the leading European biotech cluster 15. April 2016WuXi AppTec Acquires Crelux 2015 5. October 2015Evotec awarded multi-year contract to manage National Cancer Institute Chemical Biology Consortium Screening Libraries Center 15. September 2015‘Bodyguard’ Protein Helps Protect Young RNAs 26. August 2015„Bone adhesive“ – Innovative medicine starts as BMWi-project Biopolymers shall revolutionize the treatment of bone injuries 1. July 2015Molecular diagnostics specialist GNA Biosolutions completes € 6 million (US$ 6.7m) financing round 24. June 2015CRELUX receives 800 000 euros funding within the EU HORIZON 2020 programme to identify compounds from marine sources for age-related disease therapy 2014 5. December 2014ChromoTek strengthens its position in the highly important US market 24. July 2014CRELUX and 4SC Discovery awarded research grant for new epigenetic cancer drugs 28. May 20144SC announces positive top line data from clinical Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO 24. March 2014ChromoTek and NMI TT ally to start a new chapter in cellular high content analysis 2013 10. December 2013Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim 21. October 2013Evotec enters integrated alliance with AstraZeneca in kidney disease 16. October 2013Evotec to hold R&D Day 2013 10. October 2013Evotec and Harvard University to collaborate on exploration of enteroendocrine signals affecting key metabolic pathways 30. September 2013Evotec receives clinical milestone as part of its discovery alliance with Boehringer Ingelheim 10. September 2013SuppreMol appoints industry expert Michael Tansey as Chief Development Officer 8. August 2013Evotec AG reports H1 2013 results 8. August 20134SC reports second quarter 2013 financial results 1. August 20134SC to host conference call on 8 August 2013 to present half year results 2013 25. July 20134SC’s partner Yakult Honsha starts clinical Phase I/II study with cancer compound resminostat in non-small-cell lung cancer (NSCLC) in Japan 21. May 2013SuppreMol Raises € 9.5 million in Extended Series D Financing Round 16. May 2013Evotec and Harvard University to collaborate on development of new class of antibacterials 14. May 20134SC significantly improves operating result in first quarter of 2013 and resolves to focus its development strategy 10. May 20134SC to host conference call on 14 May 2013 to present first quarter results of 2013 30. April 2013Dana-Farber’s Belfer Institute for Applied Cancer Science and Evotec establish collaboration in oncology 18. April 2013ChromoTek wins INDUSTRY PRIZE 2013 for its pioneering Chromobody® technology for the real time analysis of cellular molecules in live cells 26. March 2013Forward step by step with Action Plan 2016 – Continued revenue growth – Significant pipeline progress 25. March 20134SC announces financial results for a successful year 2012 18. March 20134SC to host conference call and webcast on 25 March 2013 to present full year financial results for 2012 11. March 2013ibidi is a Top Winner in the 2012/13 German Economy Innovation Award Competition 6. March 20134SC AG: Dr Ulrich Dauer to step down as CEO and member of the Management Board on 31 March 2013; his successor will be CFO Enno Spillner 26. February 20134SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases 20. February 20134SC Discovery and BioNTech launch strategic cancer therapy research partnership 11. January 2013Evotec achieves milestone in drug discovery collaboration with Ono Pharmaceutical Co., Ltd. 9. January 2013Evotec and Yale University form Open Innovation Alliance 8. January 20134SC obtains key patent for anti-cancer compound resminostat in Europe 7. January 2013Evotec expands collaboration with MedImmune, receives milestone payment 3. January 2013Evotec acquires Cell Culture Service GmbH 2. January 2013Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy 2012 17. December 2012Evotec announces NMDA antagonist license agreement 28. November 2012Evotec enters biology collaboration with Probiodrug 23. November 2012Evotec Receives CIR (French Research Tax Credit) Accreditation 8. August 2012Evotec H1 2012: Building innovation on the back of profitable growth 28. June 20124SC to present additional safety and efficacy data for cancer drug Resminostat from its Phase II SHELTER trial in liver cancer at ESMO GI Cancer Meeting 2011 21. December 2022Innovation and Start-Up Center for Biotechnology (IZB) welcomes T-CURX GmbH 22. November 2022Atriva Therapeutics GmbH moves into the Innovation and Start-Up Center for Biotechnology (IZB) 9. November 2022Venture Capital Magazine 06-22 9. November 2022Venture Capital Magazine 06-22 28. October 2022Süddeutsche Zeitung 2022 20. October 2022Innovation and Start-Up Center for Biotechnology (IZB) welcomes consultancy KLIFO 17. October 2022VC investor Andera Partners opens office in the Innovation and Start-up Center Biotechnology (IZB) 12. October 20227th Munich Life Science Pitch Day 12. October 202215th Biotech Press Lounge 7. October 2022Munich Life Science Pitch Day at the IZB: Eleven teams presented to 28 life science investors with an available investment volume of more than 20 billion euros 7. October 20227th Munich Life Science Pitch Day 1. October 202215th Biotech PressLounge 1. October 202215th IZB Biotech Press Lounge: The cocktail for medical progress 1. August 2022Newsletter August 2022 22. July 2022IZBrunch vom 21. Juli 2022 14. July 2022Cutting-edge research at Munich’s IZB attracts strong interest 5. July 2022IZBrunch June 30, 2022 22. June 2022Wirtschaftsempfang / Economic reception 2022 22. June 2022Business reception at the Biotechnology Innovation and Start-up Center (IZB) above the roofs of the campus 3. May 2022Newsletter Mai 2022 3. May 2022Tubulis closes a series B financing in the amount of 60 million and moves into IZB in June 2022 14. April 2022Interview Dr. Zobel, münchenTV 1. April 2022Newsletter April 2022 31. March 202214th Biotech Press Lounge 23. March 202214th Biotech Press Lounge 23. March 202214th Biotech Press Lounge of the IZB: Medical innovations that are changing the world 27. February 2022Newsletter February 2022 24. February 2022Innovation and Start-Up Center for Biotechnology (IZB) welcomes new start-up Origin.Bio 31. January 2022Newsletter January 2022 31. January 2022Süddeutsche Zeitung 2022 28. January 2022Munich’s Biotech Valley IZB is Booming 20. January 2022SCG Cell Therapy expands global R&D by opening a research innovation site at the IZB in Germany 19. January 2022PreOmics receives Euro 13.5 million from Bruker Corporation in Series B financing round 30. November 2021Newsletter November 2021 5. November 2021IZBrunch, October 21, 2021 3. November 2021Eisbach Bio receives 6.7 million Euros grant from the Bavarian Government 11. October 2021Newsletter October 2021 6. October 2021mk2 Biotechnolgies new start-up at the Innovation and Start-up Center Biotechnology (IZB) in Martinsried, near Munich, Germany 5. October 2021IZBrunch, September 23, 2021 5. October 20216th Munich Life Science Pitch Day 1. October 2021Innovative drug developers presented to over 20 investors at the Munich Start-Up Center 1. October 20216th Munich Life Science Pitch Day 8. July 2021COVID-19: Start-up Eisbach Bio at the IZB receives EUR 8 million government grant 5. July 202130.09.2021: Life Science Pitch Day in cooperation with High-Tech Gründerfonds, Bayer AG, Boehringer Ingelheim and IZB 1. July 2021Biotech start-ups at the IZB close deals worth more than 140 million EUR in the first half of 2021 12. May 2021AMSilk receives financing of 29 million euros 13. April 2021Lindis entwickelt Immuntherapie gegen Blasenkrebs 13. April 2021Lindis Biotech develops immunotherapy against bladder cancer 17. March 2021CHEManager 2021 10. March 2021Münchner Merkur 2021 1. March 2021Origenis founds biotech company Neuron23 in Silicon Valley together with star investor Kleiner Perkins 25. February 2021ChromoTek and Absolute Antibody Collaborate on Recombinant Engineered Antibodies 11. February 2021A higher omega-3 level apparently protects from dying from COVID-19 4. February 2021World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools 3. December 2020Innovation network Proteomics4Future explores new technologies for the industrialization of MS-based proteomics 23. November 2020Proteintech uand Chromo Tek, 2020 23. November 2020Handelsblatt, 2020 23. November 2020IHK Magazine, 07-2019 23. November 2020Welt am Sonntag, 2020 23. November 2020IHK Magazine, 2019 23. November 2020Die Festschrift zum 25-jährigen Jubiläum des IZB präsentiert 70 Portraits und Visionen erfolgreicher Biotech-Start-ups 20. November 2020IZB press photos 20. November 2020Commemorative publication of the IZB 10. November 2020Festschrift for the 25th anniversary of the IZB 10. November 2020CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients 21. October 2020Proteintech Acquires ChromoTek, Expanding its Next Generation Antibody Tools 14. October 2020Florian Hahn, MdB, visited the corona researchers in the Innovation and Start-up Center for Biotechnology (IZB) near Munich 28. September 202013th Biotech Press Lounge 25. August 2020Visit of the Minister Kerstin Schreyer to the IZB 25. August 2020Economic reception 2019 in the IZB 25. August 2020Economic reception 2018 in the IZB 25. August 2020Economic reception 2017 at the IZB 25. August 20201. Refresh Meetup with Labiotech.eu 25. August 2020Economic reception 2015 in the IZB 25. August 2020Visit of the State Secretary for Economic Affairs Franz Joseph Pschierer to the IZB 25. August 2020Innovations Congress “Biotech made in Germany” 25. August 2020Opening of the IZB Residence CAMPUS AT HOME 25. August 2020Imagebrochure of the IZB 23. August 2020Restaurant Seven and More press photos 17. August 2020At the IZB, start-ups are working on drugs against the Sars-CoV-2 virus, as part of a consortium on a vaccine and developing new corona tests 6. August 2020MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation 3. August 2020Image video of the IZB 29. July 2020IZB In Dialog 02/2019 18. June 2020Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19 15. May 2020Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients 2. May 2020Brochure Conference Location 29. April 2020Brochure of the G2B Faculty Club 23. April 2020Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 21. April 2020GALLERY Freshmaker 21. April 2020Campus hotel press photos 21. April 2020G2B Faculty Club press photos 19. April 2020GALLERY Seven-and-more 18. April 2020GALLERY SkyRoom 17. April 202013th Biotech Press Lounge 17. April 202012th Biotech Press Lounge 16. April 202011th Biotech Press Lounge 29. March 2020Brochure CAMPUS AT HOME 16. February 202013th Biotech Press Lounge at Faculty Club G2B 17. October 201912. Biotech Press Lounge at Faculty Club G2B
